Arginyl-tRNA synthetase and ribosomal A site (ArgRS/A-site)

Arginyl-tRNA synthetase (ArgRS) and the ribosomal A site represent critical components of the translation machinery. ArgRS is an essential enzyme that catalyzes the attachment of L-arginine to its cognate tRNA, a process vital for the fidelity of the genetic code. The ribosomal A site is the entry point for these aminoacyl-tRNAs during the elongation phase of protein synthesis. Drugs targeting this dual system, such as the antibiotic Blasticidin S, typically function by mimicking the arginyl-adenylate intermediate or the aminoacyl-tRNA terminus to inhibit either the charging of tRNA or the peptide bond formation within the ribosome. Because these processes are fundamental to life, they are primary targets for the development of antimicrobial and antifungal agents. However, therapeutic design must ensure high selectivity for microbial components over human cytosolic and mitochondrial counterparts to minimize systemic toxicity.

Other names

L-arginyl-tRNA synthetaseArginine--tRNA ligaseArgRSRibosomal aminoacyl siteRibosomal A-site

Inhibition of protein synthesis by blocking the aminoacylation of tRNA and/or preventing the proper binding and translocation of aminoacyl-tRNA at the ribosomal A site.